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Introduction
Breast cancer development involves multiple poorly understood steps (25) . Currently, several genes that may participate in breast cancer development are under investigation. The ras family of genes has been implicated in many different cancers and has also been observed to be overexpressed in human breast cancer (6, 10, 13, 16) . Interestingly, many cancers are associated with a specific member of the ras gene family (i.e. H-ras, K-ras, or N-ras) (12) . For example, in humans, activation of the H-ras gene is found in bladder cancer (21) , K-ras gene activation is found in colon (2, 9) and pancreatic cancers (4) , and N-ras gene activation is found in hematopoietic cancers (3) .
Therefore, ras genes play a central role in many different cancers. The goal of this research was to further characterize the role of the ras genes in mammary carcinogenesis.
The rat mammary carcinogenesis model is commonly used for investigations in breast cancer (11) . Previous studies have found that the H-ras gene is frequently mutated in mammary tumors that result following the administration of chemical carcinogens (e.g. nitrosomethylurea or dimethylbenzanthracene) to rats (19, 24) . This high frequency of activation implicates ras as an initiation lesion in mammary carcinogenesis (24) . Previous reports have found that the direct introduction of an activated Harvey ras gene into the mammary gland results in mammary carcinoma formation (22) . In addition, carcinoma development was observed following the introduction of the wild-type Harvey ras gene into the mammary gland (20) . This may be more analogous to the overexpression of Ras as found in human breast cancer (6, 10, 13, 16 ). Yet, the steps and mechanisms that lead to the aberrant function of ras genes in cancer are poorly understood. The purpose of this work was to further define the steps important to selective ras activation in the rat mammary carcinogenesis model. This was accomplished by comparing the carcinogenicity of two closely related ras family members using the rat mammary carcinogenesis model. That is, by comparing the carcinogenicity of H-ras, which is associated with mammary tumor development, to the K-ras, which has not been found to play a role in rat mammary carcinogenesis.
Although the H-Ras and K-Ras proteins are highly homologous, regions of variation in the two proteins are present, especially in the final 20 amino acids of the carboxyl terminus (1) . To study the tumorigenic potential of ras genes, retroviral vectors were used to introduce either wildtype or activated H-ras or K-ras genes to the mammary parenchyma via the central lacteal. Previous studies have shown that the tumorigenic potential of the retrovirally expressed oncogene is proportional to the virus titer that is instilled into the mammary gland (23) . Therefore, the potency of the H-ras and K-ras genes to form mammary carcinomas can be compared. Resultant tumors can then be histologically and molecularly characterized.
Another step that may contribute to the tissue selective association of an oncogene is the mutability of the genes at the DNA level. Previous studies have reported differences in DNA methylation patterns between the H-ras and K-ras genes in rat mammary tissue following nitrosomethylurea exposure (15) . Both genes showed alterations in methylation patterns, although the H-ras gene was more sensitive to these effects in the mammary gland. In this report, a clonogenic transplantation assay (7) was used to investigate mutation induction by a carcinogen with a target gene. DNA was extracted from transplant growths that resulted from the introduction of mammary clonogens into the intrascapular fat pad of hormonally primed recipient rats. A variation of the PCR-based method developed by Cha et al (5) was used to determine whether DNA from the growths harbored a mutated H-ras gene. Thus, the relative percentage of H-ras gene mutations in the mammary gland after carcinogen exposure can be determined. This information also provides an estimate of the relative penetrance of the H-ras gene for tumor formation versus mutation frequency.
Gene expression regulation largely defines the activity of a gene within a tissue type.
Therefore, control of gene expression may be a major contributor to the selective association of an oncogene with a particular tumor type. Previous studies have shown that the K-ras gene is expressed at lower levels than the H-ras gene in rat mammary tissue (15) . Yet, due to the many cell types and the different developmental stages of a particular cell type in the mammary gland, it cannot be concluded that the overall gene expression levels for the gland reflect expression levels for the breast cells important in tumor development.
To investigate the role of H-ras gene regulatory elements in the tissue-specific association of H-ras gene activation in rat mammary carcinogenesis, a transgenic animal model was developed that uses H-ras gene regulatory elements to drive expression of the rat K-ras gene. To validate this model, it was first necessary to develop a transgenic rat line that contains a H-ras transgene under the same regulatory elements as those used to drive expression of the K-ras transgene (i.e. H-ras gene regulatory elements). For each group, animals were characterized for expression of the transgene, transfer of the transgene through the germline in a Mendelian fashion, and determination of any anomalies that might arise from animals harboring the transgene, such as disease susceptibility, increased cancer incidence, and changes in lifespan. Acceptable transgenic lines were exposed to carcinogen and resultant tumors were assayed for mutation of the transgene and the endogenous H-ras gene.
This proposal addresses a fundamental question of cancer biology that has direct value to breast cancer. The results from these studies will help in understanding factors important in controlling the association of oncogenes with a specific tumor type. It is hoped that this information will also provide insight for the development of organ specific prevention and therapeutic strategies.
Body
The three major objectives of this study were designed to further characterize events important in the selective activation of the H-ras gene as found in rat mammary carcinomas following exposure to the chemical carcinogen nitrosomethylurea (NMU). This selectivity was investigated by comparing the H-ras gene to the K-ras gene, which is closely related but not activated, in rat mammary carcinogenesis. The first set of experiments determined whether or not the ras gene products induce rat mammary tumors. The second objective was to determine the relative mutation frequency of the H-ras and K-ras genes in rat mammary transplants following carcinogen exposure. The final set of experiments investigated the role of H-ras gene regulation in chemically induced rat mammary carcinogenesis.
The first set of experiments determined whether H-ras and K-ras, in their wild-type and activated forms, could induce rat mammary carcinomas. This was done using methods developed in our laboratory using replication-defective retroviral vectors to deliver the ras genes directly to the mammary parenchyma through the 12 teats of sexually mature female Wistar Furth rats (22) . This methodology stemmed from experiments performed to ablate the mammary parenchyma by injecting ethanol into the central mammary duct, thus allowing the cleared fat pad to be used for mammary cell transplantation studies (Jane Yasukawa-Bames, personal communication). For effective infusion, the female rat must be sufficiently mature to allow recognition of distinct teats (i.e. rats must be approximately 40 days of age or older). The teat is clipped and the remaining orifice is cannulated using a syringe with a blunt-ended 27 gauge needle. Ten to 20 11l of viral stock are infused in a pigmented solution that is used to allow the determination of injection efficiency. After injection, the teat is held shut with forceps for several seconds to reduce reflux.
Replication-defective retroviruses were used to deliver expression vectors to the mammary parenchyma. The retroviral vectors used in this study are illustrated in Appendix 1. The activating mutation present in the ras gene of the JRHrasA and JRKrasA constructs is representative of the G to A transition mutation found in the second basepair of codon 12 (G35 to A) of ras genes following NMU exposure. Mammary carcinoma development was assessed for 18 weeks after virus infusion. In our initial study, using viruses at titers ranging from 3x106 to 6x106 CFU/ml, infusion of the activated form of both the H-ras (JRras and JRHrasA) and the K-ras (JRKrasA and JRKrasV) genes resulted in efficient carcinoma formation (Appendices 2 and 3).
Histological analysis of tumors resulting from infusion of both vectors found they were mammary carcinomas (data not shown). The molecular biological procedures used in these studies were standard molecular biological techniques (17) . Polymerase chain reaction (PCR) analysis was used to confirm the presence of viral DNA in the resultant tumors by amplifying the neomycin resistance gene, which is unique to the retroviral vectors. All tumors evaluated were found to carry vector DNA (data not shown). Although the viral titer was comparable for these vectors, the tumor multiplicity was greater for vectors expressing the H-ras gene (i.e. JRras) than for the K-ras gene (i.e. JRKrasG, JRKrasA, or JRKrasV -Appendix 3).
Tumors also resulted from infusion of vectors expressing wild-type H-ras (JRHrasGAppendix 2), but not wild-type K-ras (JRKrasG -Appendix 3). On histological analysis of the wild-type H-ras generated tumors, regions of keratinization were observed (20) . This has not previously been observed in tumors resulting from infusion of activated H-ras. Tumors resulting from the infusion of the wild-type H-ras gene were also small, slower growing, had a longer latency and slightly lower multiplicity compared to mammary tumors resulting from the infusion of the activated form of the H-ras gene (Appendix 2). DNA sequencing from 3 tumors of the retrovirally expressed Harvey ras gene (i.e. from JRHrasG) found no mutations present from codons 12 through 61 (data not shown). Due to the small tumor size and low multiplicity of these tumors, not all of the necessary evaluations could be completed from the initial study, therefore, another study will be carried out to characterize carcinogenesis with wild-type H-ras gene from the JRHrasG vector.
A second study using the activated forms of H-ras (JRHrasA) and K-ras-2B (JRKrasA) expressing vectors was performed using equivalent viral titers (7x106 and 8x10 6 CFU/ml, respectively). Again, the H-ras gene led to tumor development with greater multiplicity and shorter latency than by the K-ras expressing vector (Appendix 4). By comparing the level of tumorigenesis of the two vectors after infusion, the H-ras oncogene was found to be 5-to 10-fold more potent than the comparably activated K-ras gene product at inducing rat mammary carcinomas. A final study was carried out using the activated forms of H-ras and K-ras-2B vectors at 6x10 6 and 3x10 7 CFU/ml, respectively. Although the K-ras expressing vector was infused at a 5-fold higher titer, the H-ras expressing vector still led to double the number of tumors by 18 weeks after infusion (Appendix 5). All mammary tumors resulting from these studies were evaluated for histopathology and found to be mammary carcinomas (data not shown).
The second objective was to determine the percentage of H-ras and K-ras genes activated in the target cells believed responsible for mammary tumor development (i.e. mammary clonogens).
This technique uses a mamnmary transplantation assay developed in our lab (7) . Donor rats were treated with 50mg/kg NMU. Twenty-four hours later, abdominal and inguinal mammary glands were removed and de-aggregated in collagenase for 2 to 3 hours. Mammary tissue was then washed to remove the remaining fat, digested briefly (-5 min) in 0.1% trypsin, and single-cells were obtained after filtering through a 53g mesh. Cells were counted using a hemacytometer and resuspended in brain homogenate to a concentration of 106 cells per 60 gl. Sixty gl of mammary cell suspension was then injected using a 23gi needle into 3 independent sites of the intrascapular fat pad of hormonally-primed (i.e. rats treated with mammotropic pituitary tumor) recipient 50 day old female Wistar-Furths rats. Mammary growths were allowed to develop in the fat pad for 1 month, at which time they were removed and stored at -80 0 C until DNA extraction. This DNA was analyzed for G35 to A transition mutations in the H-ras or K-ras gene (as observed in NMU initiated tumors) using the mismatch amplification mutation assay (MAMA) developed by Cha et al (5).
Our initial studies indicated that there was potentially a problem with efficient clonogen growth when large numbers of cells are delivered to a single fat pad location. Therefore, cells expressing a unique marker (cells infected with a retroviral expression vector as described in the first objective) were instilled in the fat pad at varying numbers. The presence of the marker in resultant fat pad growths was determined using PCR to amplify sequences unique to vector DNA.
Marker DNA was detected in all growth resulting from the instillation of up to 1000 clonogenic cells (data not shown). Therefore, 1,000 clonogenic cells (i.e. 106 total mammary cells) were infused per each of 3 instrascapular fat pad locations per a recipient animal.
Ninety-three transplant sites were isolated from control (non-NMU-exposed) growths and 108 transplant sites were isolated from NMU-exposed donor growths. These transplants were prepared for DNA extraction and stored at -80'C. Currently, DNA is being extracted from these samples with care taken not to contaminate the preparations with previously generated PCR products. PCR product contamination is a common problem in PCR-based evaluations with the sensitivity required for this analysis. Following DNA extraction, these samples were tested for the percentage of G35 to A activating mutations in the ras genes of unexposed and NMU-exposed transplants.
This objective was delayed by several mishaps. Initially, the mammotropic tumor that was maintained in this laboratory was lost in a liquid nitrogen tank that dried up. Several months were required to regenerate a mammotropic tumor adequate for these studies. Also, the assay originally used to screen for mutations in the ras genes was not sufficiently sensitive. Therefore, a second assay has been developed (i.e. the MAMA assay) that provides the required sensitivity to screen for G35 to A Harvey ras gene mutations. Currently, a preliminary estimate of 1 in 105 mammary cells have been found harboring G35 to A mutations in the Harvey ras gene (data not shown). However, we also believe that the MAMA assay needs to be validated before this estimate is acceptable. In the first transgenic rat mammary carcinogenesis study, 34 female R8 HrHr transgenic rats and 37 non-transgenic littermates were treated with 50mg/kg NMU at 42 to 50 days of age. Tumor development was assessed weekly for 18 weeks following NMU exposure and tumors reaching 10 mm in diameter were removed. Tumor samples were prepared for histological analysis and samples were stored at -80°C until DNA extractions were performed. Allele-specific oligonucleotide hybridization was used for the original evaluation of H-ras mutations in carcinomas that developed in non-transgenic animals (25) . PCR product was transferred to a nylon blotting membrane and selective hybridization was carried out using a probe to screen for a G35 to A mutations in the Hras gene. In addition, another PCR-based method was developed that recognizes the generation of a unique restriction site in PCR-products from amplification of DNA containing the G35 to A transition mutation in the ras genes (14) . This method was used to screen for G35 to A mutations in both the endogenous H-ras genes and the transgenes of mammary tumors that developed in the HrHr and HrKr transgenic rats.
For statistical analysis of carcinoma development, Kaplan-Meier survival curve estimates were determined for each group. The time without tumor was determined for each group and used to compare the number of expected and observed events using a log-rank test. Pairwise comparisons were made using a log-rank test. If global comparisons at 3/4 or at the end of a study were significant, then a one-way analysis of variance for global comparison of each group was performed, followed by least significant difference pairwise comparison.
The latency of carcinoma development was significantly greater for HrHr transgenic animals compared to non-transgenic littermates (P<0.05 -Appendix 8A). Also, at 18 weeks, the multiplicity of tumor development in the HrHr transgenics was 50% that of non-transgenic controls (Appendix 8B). Examination of endogenous H-ras gene activation in tumors from non-transgenic animals showed that 55% possessed G35 to A mutations. The frequency of endogenous H-ras gene mutation in the tumors derived from HrHr transgenics was found to be 58%. Only 1 G35 to A transition mutation was found in the HrHr transgene in any of the tumors screened (Appendix 10).
In a study analogous to that performed with the HrHr transgenics, a mammary carcinogenesis study was performed with the 4321 HrKr transgenic animal strain since this strain is similar to the R8 transgenics in transgene copy number and mammary gland Ras expression This concludes the results currently available for these studies. Several related studies are in progress. These include further characterization of the transgenic rat lines obtained during this study. To validate the results obtained with the first set of HrHr and HrKr transgenic rats, a second carcinogenesis study with the R8 and 4321 transgenic lines is in progress. Also, to determine whether these results are line specific, other HrHr and HrKr transgenic lines produced are being prepared for carcinogenesis studies. Also, a retroviral vector study to further investigate carcinogenesis by wild-type H-ras (JRHrasG) will be carried out.
In summary, the data provided in these studies further describe molecular events that contribute to the multistage process of mammary carcinogenesis. The most substantial finding was that Harvey ras is more potent than the closely related Kirsten ras in mammary carcinogenesis. Previous in vitro studies have shown the potential for differential activities of the ras family members, though this is the first study to directly illustrate the differential oncogenic potencies of Harvey ras and Kirsten ras in vivo. These results provide a basis for further investigations in the molecular mechanisms of carcinogenesis and the development of therapies directed at specific ras proteins for cancer treatment.
Conclusions
The first objective of this proposal was to determine the mammary carcinogenic potential of the K-ras gene. It has been observed that an activated H-ras gene can induce tumor development in the rat mammary carcinogenesis model (22) . Yet, the carcinogenic potential of the K-ras gene in rat mammary carcinogenesis is not known. Therefore, retroviral vectors expressing activated forms of the K-ras gene product were constructed. Vectors expressing the activated H-ras gene were used as a positive controls for mammary carcinogenesis and, as expected, mammary tumors developed efficiently from infusion of the retroviral vector expressing the H-ras gene. Mammary tumors also developed from infusion of the vectors expressing the activated K-ras genes, but with lower efficiency than the H-ras gene expression vector. Therefore, although the activated K-ras gene is capable of leading to mammary carcinoma development, it is less potent than the activated H-ras gene in mammary carcinogenesis.
To better estimate the potency of the activated K-ras gene compared to activated H-ras, two additional studies were conducted. In the first study, vectors expressing either H-ras and K-ras-2B with a G35 to A transition mutation were used at comparable viral titers. Mammary tumors induced by the activated H-ras vector had a shorter latency and greater multiplicity than tumors induced by the comparable K-ras vector. Furthermore, when the activated K-ras virus was infused at a 5-fold higher titer than the activated H-ras vector, carcinoma development from infusion of the H-ras vector still resulted in twice as many mammary carcinomas at 18 weeks. Thus, the G35 to A activated form of the H-ras gene is at least 5 times more potent than the comparably activated form of the K-ras-2B gene in mammary carcinogenesis. Yet, the activated K-ras gene was still effective at inducing mammary carcinomas. Thus, the absense of K-ras activation in mammary carcinogenesis is not due to the inability of the K-ras gene product to lead to mammary tumor development.
The second objective was to determine the percentage of H-ras and K-ras gene mutations induced by nitrosomethylurea in mammary clonogenic transplants. Our initial study established that 1000 clonogens could efficiently be transplanted to a fat pad site. Several complicating factors have hindered the completion of this objective. To date, mammary fat pad growths have been collected and DNA extraction have been carried out. Analysis for the percentage of transplants with H-ras and K-ras gene activation was recently performed, but these results must be validated before conclusions can be drawn. Therefore, this data is preliminary and not included in this report. On evaluation of ras gene activation in the resultant mammary tumors, it was observed that the endogenous H-ras gene was mutated as previously reported (24) The studies presented here clearly show differences between H-ras-and K-ras-induced carcinogenesis that should prove valuable in understanding the molecular and cellular events that lead to breast cancer. In particular, expression of mutated H-ras is more effective at mammary tumor development than the analogous mutant form of K-ras. Additional studies in understanding why these two highly homologous proteins differ in efficiency of tumor development are necessary.
These studies should assist in the development of modalities for breast cancer prevention, diagnosis, and treatment. 
